BCG vaccine in insulin-dependent diabetes mellitus [6]

Lancet

Volumn 349, Issue 9064, 1997, Pages 1520-1521

  Pozzilli, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; C PEPTIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN; NICOTINAMIDE;

ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRADERMAL DRUG ADMINISTRATION; LETTER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION;

EID: 0030989245     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62100-9     Document Type: Article

References (5)

1. Shehadeh N, Calcinaro F, Bradley BJ, et al. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 1994; 343: 706-07.
2. Williams G. IDDM: long honeymoon, sweet ending. Lancet 1994; 343: 684-85.
3. Pozzilli P, Visalli N, Signore A, et al. Combination of nicotinamide and steroid versus nicotinamide in recent onset insulin-dependent diabetes (The IMDIAB II Study). Diabetes Care 1994; 17: 897-900.
4. Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent onset insulin dependent diabetes mellitus. Diabetologia 1995; 38: 848-52.
5. Pozzilli P, Browne PD, Kolb H, and the Nicotinamide Trialists. Metaanalysis of nicotinamide treatment in patients with recent onset insulin dependent diabetes. Diabetes Care 1996; 19: 1357-63.